{
  "metadata": {
    "export_date": "2026-01-05T06:54:30.499428",
    "patient_profile": {
      "age": 65,
      "sex": "male",
      "cancer_type": "NSCLC",
      "biomarkers": [
        "KRAS G12C"
      ],
      "description": "65-year-old male diagnosed with Stage IV non-small cell lung cancer (adenocarcinoma) in March 2024. KRAS G12C mutation confirmed by NGS (FoundationOne CDx). Initial treatment with carboplatin/pemetrexed + pembrolizumab x6 cycles achieved partial response. Progressive disease noted on surveillance CT in November 2025 with new hepatic metastases. Currently asymptomatic with mild dyspnea on exertion. No history of autoimmune disease. Former smoker (30 pack-years, quit 2019). Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k."
    },
    "total_trials": 100,
    "high_likelihood": 26,
    "medium_likelihood": 3
  },
  "results": [
    {
      "nct_id": "NCT05853575",
      "title": "A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1",
        "Prior therapies: carboplatin/pemetrexed, pembrolizumab",
        "Brain metastases: none"
      ],
      "conflicts": [],
      "uncertainties": [
        "Blood test results: creatinine, LFTs, ANC, platelets are provided but categorization of recovery from prior treatment is unclear."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type is NSCLC and includes the required KRAS G12C mutation. The patient has received prior treatment with carboplatin and an immune checkpoint inhibitor. There are no ongoing brain metastases or concerning blood test results, suggesting likely recovery from prior therapies.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06162221",
      "title": "A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "Revolution Medicines, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "ECOG status: 1",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "Prior therapies: carboplatin/pemetrexed, pembrolizumab",
        "No brain metastases"
      ],
      "conflicts": [],
      "uncertainties": [
        "Organ function (Creatinine, LFTs are normal but not explicitly outlined if considered adequate by study)",
        "Study specific adequacy of organ function not confirmed"
      ],
      "confidence": 0.85,
      "reasoning": "The patient has NSCLC (which matches the trial's focus) and is KRAS G12C-mutated, fulfilling the biomarker requirement. The ECOG status and age meet the eligibility requirements. The history of treatment does not contradict the inclusion criteria. However, organ function adequacy is not explicitly confirmed, warranting some uncertainty.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06881784",
      "title": "RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC",
      "sponsor": "Revolution Medicines, Inc.",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age is 65 (acceptable age for trial)",
        "ECOG status is 1",
        "Cancer type is NSCLC (pathologically confirmed)",
        "Has measurable disease per RECIST v1.1",
        "Adequate organ function: creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k",
        "Has documented RAS mutation status (KRAS G12C)",
        "Patient has had one prior line of therapy including an anti-PD-1 agent (pembrolizumab) and platinum-based chemotherapy (carboplatin/pemetrexed)"
      ],
      "conflicts": [
        "Patient has prior therapy with pembrolizumab which is an anti-PD-1 agent, hence can't receive docetaxel or direct RAS-targeted therapy."
      ],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient meets the disease type and treatment line criteria for the trial, as they have NSCLC and have received acceptable prior treatments. All eligibility criteria are met, leading to a high likelihood of eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT02178163",
      "title": "A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.",
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has Stage IV non-small cell lung cancer (adenocarcinoma).",
        "ECOG status is 1.",
        "Absolute neutrophil count is 3.2, which is above 1.5 x 10^9/L.",
        "Platelet count is 245k, which is above 100,000 x 10^9/L.",
        "Serum creatinine is 1.1, within the acceptable range.",
        "No brain metastases."
      ],
      "conflicts": [],
      "uncertainties": [
        "Serum bilirubin levels are not provided, so their status relative to ULN is unknown.",
        "Transaminase levels are not provided, so we cannot confirm if they meet the criteria."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the trial's indication for advanced NSCLC. He has prior treatment, which aligns with the inclusion of previously treated patients in the trial. His ECOG status and organ function parameters are within acceptable ranges, though certain laboratory values are unspecified.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05005403",
      "title": "A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors With Azirkitug (ABBV-514) as a Single Agent and in Combination With Budigalimab or Bevacizumab",
      "sponsor": "AbbVie",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC (non-small cell lung cancer) which is a target indication of the trial.",
        "Patient has an ECOG performance status of 1.",
        "Patient has previously received standard of care therapy (carboplatin/pemetrexed and pembrolizumab) and has progressive disease.",
        "Patient has a documented KRAS G12C mutation."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial's target indication. The patient is previously treated, having progressed after standard therapies, which aligns with the trial's criteria for previously treated patients. There are no conflicts or uncertainties regarding the patient's eligibility for this trial.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05815173",
      "title": "Phase I/II Study of Ladarixin and Sotorasib in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "NYU Langone Health",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarker: KRAS G12C mutation confirmed",
        "ECOG status: 1",
        "Progressive disease following treatment with anti-PD(L)-1 with chemotherapy",
        "No brain metastases"
      ],
      "conflicts": [],
      "uncertainties": [
        "No specific organ function lab results are provided.",
        "Documentation of the presence of the KRAS G12C mutation is confirmed by NGS, satisfying the need for documentation."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the study's indication, as they have confirmed KRAS G12C mutant NSCLC. They have also demonstrated progression of disease after prior therapy, matching the treatment line criteria. All supporting factors indicate eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06343402",
      "title": "A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-8520 in Subjects With Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study",
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Histologically documented advanced stage IV non-small cell lung cancer with KRAS G12C mutation",
        "ECOG performance status of 1"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC, KRAS G12C), prior treatment with pembrolizumab, and ECOG status all align with the trial's inclusion criteria. Additionally, the patient has no untreated brain metastases, maintaining trial eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05410145",
      "title": "A Phase 1/2, Open Label, Dose-escalation, and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",
      "sponsor": "D3 Bio (Wuxi) Co., Ltd",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a confirmed diagnosis of metastatic NSCLC.",
        "Patient has documented KRAS G12C mutation identified within the last 5 years.",
        "Patient has an ECOG performance status of 1.",
        "Patient has adequate organ and marrow function.",
        "Patient has measurable disease as evidenced by progressive disease noted on surveillance CT."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type is NSCLC, which aligns with the trial's focus on KRAS p.G12C mutations. The patient has previously received treatment but this trial allows previously treated patients, and all other criteria are met, leading to strong confidence in eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05786924",
      "title": "A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",
      "sponsor": "Institut de Recherches Internationales Servier",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has Stage IV NSCLC which matches the study condition of non-small cell lung cancer.",
        "Patient has a confirmed KRAS G12C mutation as required by the trial.",
        "Patient's ECOG status is 1, indicating acceptable performance status.",
        "Patient does not have brain metastases."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient has a confirmed diagnosis of Stage IV NSCLC and possesses the KRAS G12C mutation, which aligns with the trial's eligibility criteria. The patient's treatment history also suggests they can fit into the treatment line required for the trial.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06244771",
      "title": "An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors",
      "sponsor": "Frontier Medicines Corporation",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC with KRAS G12C mutation",
        "ECOG status is 1",
        "Patient has adequate hematological function",
        "No brain metastases"
      ],
      "conflicts": [
        "None"
      ],
      "uncertainties": [
        "Renal and hepatic function specifics are not provided"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC with KRAS G12C mutation) matches the trial's inclusion criteria. The patient is previously treated, which aligns with the trial's requirement for previously treated patients with progression on standard therapies. The ECOG performance status is acceptable, and no brain metastases are present, although details on renal and hepatic function are unspecified.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06814496",
      "title": "RAdiation comBined With BIspecific T-Cell Engager in DLL3 Expressing Tumors (RABBIT) Study: A Phase I/II Study of AMG757 / Tarlatamab and Concurrent Radiation Therapy in Tumors With High Prevalence of DLL3",
      "sponsor": "University of Arizona",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC, which is included in the trial conditions.",
        "Patient is 65 years old, which is over 18 years of age.",
        "ECOG status is 1, which is within the acceptable range (0-2).",
        "Patient has prior therapy (pembrolizumab) and meets the inclusion requirement of having progressed after at least one line of therapy.",
        "Patient has a minimum life expectancy of more than 12 weeks.",
        "Patient is asymptomatic with mild dyspnea on exertion, which does not qualify as substantial symptoms.",
        "Patient has no history of autoimmune disease."
      ],
      "conflicts": [],
      "uncertainties": [
        "Need verification on whether the patient's lesion is measurable as defined by RECIST 1.1.",
        "Confirmation on whether the patient is eligible for external beam radiation therapy to a previously unirradiated measurable lesion."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the conditions studied in the trial. They also meet the age, ECOG performance status, treatment line requirements, and have no contraindicating medical history. Remaining uncertainties concern specific eligibility details related to measurable lesions and radiation therapy eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06973564",
      "title": "A Phase 1/2a, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of JAB-23E73 in Adult Patients With Advanced Solid Tumors With KRAS Alteration",
      "sponsor": "Jacobio Pharmaceuticals Co., Ltd.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1",
        "Prior therapies: carboplatin/pemetrexed, pembrolizumab",
        "No brain metastases",
        "Life expectancy \u22653 months",
        "Has at least one measurable lesion (hepatic metastases)"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the study indication, and they have the required KRAS alteration (G12C). The patient is >18 years old, has a suitable ECOG status, and prior therapies align with criteria for previously treated patients, indicating they likely qualify for the trial.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT00068003",
      "title": "Cell Harvest and Preparation for Surgery Branch Treatment Protocols",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": null,
      "status": "Enrolling by invitation",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC, which is included in the trial conditions studied.",
        "Patient has ECOG status of 1, which is acceptable for the trial.",
        "Patient is 65 years old, which meets the age criteria.",
        "Patient has no brain metastases."
      ],
      "conflicts": [],
      "uncertainties": [
        "HIV serology status is not provided.",
        "Hepatitis B and C serology status is not provided."
      ],
      "confidence": 0.85,
      "reasoning": "The patient's NSCLC diagnosis aligns with the trial's eligibility criteria. The patient is ECOG status 1 and aged 65, which is acceptable. There are only minor uncertainties regarding serology status for HIV and hepatitis, but overall, the patient seems likely to qualify.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05067283",
      "title": "A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC, which is the focus of the trial",
        "Patient has a confirmed KRAS G12C mutation",
        "Patient has received at least 1 line of therapy for systemic disease (carboplatin/pemetrexed and pembrolizumab)"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's diagnosis of NSCLC with a KRAS G12C mutation aligns with the trial's focus. The patient is also previously treated, meeting the necessary treatment line criteria. There are no noted conflicts or uncertainties regarding the eligibility criteria provided.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05076760",
      "title": "Phase I Study Evaluating MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors",
      "sponsor": "Memgen, Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type is NSCLC, which is included in the trial conditions studied.",
        "ECOG status is 1, which meets the trial's eligibility criteria.",
        "Patient has progressed on prior therapy including pembrolizumab, satisfying the requirements for Part 1B or 1C.",
        "Age is 65, which is above the minimum age requirement of 18 years.",
        "Creatinine level (1.1) supports adequate organ function.",
        "ANC (3.2) and platelets (245k) meet the requirements for adequate organ and marrow function."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's NSCLC diagnosis matches the trial's indication; the patient is previously treated, which aligns with the requirements. The patient meets the ECOG and organ function criteria, with no significant conflicts or uncertainties noted.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06026410",
      "title": "Phase 1, First-in-Human, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of KO-2806 When Administered as Monotherapy and in Combination Therapy in Adult Patients With Advanced Solid Tumors",
      "sponsor": "Kura Oncology, Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1",
        "Prior therapies: carboplatin/pemetrexed, pembrolizumab",
        "Brain metastases: none"
      ],
      "conflicts": [],
      "uncertainties": [
        "Creatinine level is provided but categorized as normal",
        "LFTs are normal but specific values are not provided",
        "ANC (3.2) and platelets (245k) are provided but lack reference ranges"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's NSCLC diagnosis matches the trial's focus on advanced solid tumors, and the presence of the KRAS G12C mutation aligns with the inclusion criteria for NSCLC patients who have received prior systemic therapy. The patient has an ECOG status of 1 and is otherwise asymptomatic, indicating acceptable performance status and organ function. Although there are minor uncertainties in lab values, the overall profile supports eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06128551",
      "title": "Phase 1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRAS G12C Mutant Solid Tumors",
      "sponsor": "Revolution Medicines, Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC (non-small cell lung cancer)",
        "Patient has KRAS G12C mutation",
        "Patient has ECOG status of 1",
        "Patient has prior treatment history with chemotherapy and immunotherapy"
      ],
      "conflicts": [],
      "uncertainties": [
        "Creatinine levels and general organ function are provided but not specifically stated in terms of trial eligibility",
        "Liver function test results are normal but not specified in detail"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches exactly what the trial is studying (NSCLC with KRAS G12C mutation). The patient has also received prior therapies, which fits the trial's inclusion criteria for previously treated patients. While there are minor uncertainties regarding organ function tests, the main criteria for eligibility strongly indicate that the patient qualifies.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06400472",
      "title": "A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor \u03b1-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Diagnosis of non-small cell lung cancer (NSCLC)",
        "ECOG status of 1",
        "No brain metastases",
        "Prior treatment of carboplatin/pemetrexed and pembrolizumab"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type of NSCLC matches the trial's conditions. The patient has been treated previously, but the trial appears open to previously treated patients, and there are no conflicts with inclusion or exclusion criteria. Thus, the patient likely qualifies.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06403436",
      "title": "A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors",
      "sponsor": "TOLREMO therapeutics AG",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status 1",
        "Age 65",
        "No brain metastases",
        "Creatinine 1.1",
        "LFTs normal",
        "ANC 3.2",
        "Platelets 245k",
        "Measurable disease per RECIST 1.1 criteria implied by progressive disease after treatment"
      ],
      "conflicts": [],
      "uncertainties": [
        "Hepatic function assessments (AST, ALT not provided)",
        "Coagulation laboratory assessments (PT, PTT not provided)",
        "Life expectancy as evaluated by the Investigator"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type and treatment history align with the trial's focus on NSCLC, particularly with the KRAS G12C mutation. The patient has refractory disease, meets the ECOG criterion, and has no brain metastases, all indicating strong eligibility despite minor uncertainties regarding organ function and life expectancy assessments.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06607185",
      "title": "A Phase 1a/1b Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type is NSCLC which is studied in the trial.",
        "Has KRAS G12C mutation confirmed by NGS.",
        "ECOG performance status is 1.",
        "Currently has measurable disease with progressive hepatic metastases."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type matches the trial indication (NSCLC). The patient has prior therapy, but the trial is designed for previously treated patients. Additionally, the patient meets other requirements including biomarker presence and ECOG status.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06720987",
      "title": "A Phase 1/1b, Open-label, Multicenter, Dose Escalation and Dose Optimization Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB365 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies With KRAS G12S or G12C Mutations",
      "sponsor": "Kumquat Biosciences Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC which is a solid tumor malignancy.",
        "Patient has KRAS G12C mutation.",
        "Patient has unresectable or metastatic disease.",
        "Patient has adequate organ function as indicated by normal LFTs and creatinine.",
        "Patient meets ECOG status requirement (ECOG 1).",
        "Patient has no brain metastases."
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient has NSCLC, which is a solid tumor malignancy, and carries the required KRAS G12C mutation, aligning with the trial's focus. The patient has undergone prior treatments but does not require treatment-naive status, as the trial includes previously treated patients. All other criteria have been met.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06917079",
      "title": "A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects With Advanced KRAS Mutant Cancers",
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has Stage IV non-small cell lung cancer (adenocarcinoma)",
        "Patient has KRAS G12C mutation confirmed by NGS",
        "Patient has ECOG status of 1"
      ],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial indication for KRAS mutant cancers. The patient has the required biomarker (KRAS G12C), meets the ECOG performance status criteria, and does not have untreated brain metastases. Additionally, the patient is previously treated, which aligns with the trial's patient population.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT07094204",
      "title": "A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications",
      "sponsor": "Astellas Pharma Inc",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Histologically confirmed metastatic NSCLC",
        "Documented KRAS G12C mutation",
        "ECOG status of 1",
        "Received prior standard therapy with platinum-based chemotherapy and checkpoint inhibitor therapy"
      ],
      "conflicts": [],
      "uncertainties": [
        "Verification of adequate organ function based on lab values"
      ],
      "confidence": 0.85,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial's indication for KRAS-mutated non-small cell lung cancer, and the patient has prior treatments consistent with eligibility. All primary criteria appear to be met, but clarification on lab values for organ function is needed.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06265285",
      "title": "Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program",
      "sponsor": "Mayo Clinic",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type: NSCLC matches the conditions studied",
        "ECOG status: 1",
        "Prior therapies: Patient has progressed on platinum-based chemotherapy",
        "Age: 65 (\u2265 18 years)",
        "Absolute neutrophil count (ANC): 3.2 (\u2265 1500/\u03bcL)",
        "Platelet count: 245k (\u2265 100,000/\u03bcL)",
        "Creatinine: 1.1 (\u2264 2.0 x ULN is acceptable)",
        "No history of autoimmune disease",
        "No brain metastases"
      ],
      "conflicts": [],
      "uncertainties": [
        "Serum total bilirubin and AST/ALT levels not provided to confirm liver function",
        "Residence within 35 miles of the clinic not confirmed, but the patient is in the United States",
        "Wi-Fi connectivity status not provided"
      ],
      "confidence": 0.8,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial conditions, and he is in a treatment line appropriate for the trial. Supporting factors confirm he meets key eligibility criteria, though there are minor uncertainties primarily regarding organ function and geographical requirements.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04613596",
      "title": "A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Histologically confirmed diagnosis of metastatic NSCLC with KRAS G12C mutation",
        "Patient has PD-L1 TPS of 40%",
        "No evidence of brain metastases"
      ],
      "conflicts": [
        "Patient's PD-L1 TPS is 40%, which does not meet the Phase 3 requirement of TPS >= 50%"
      ],
      "uncertainties": [],
      "confidence": 0.7,
      "reasoning": "The patient has a confirmed diagnosis of metastatic NSCLC and has a KRAS G12C mutation which aligns with the trial's inclusion criteria. However, the PD-L1 TPS of 40% does not meet the Phase 3 requirement of >= 50%, leading to some qualification concerns.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06249282",
      "title": "A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer",
      "sponsor": "City of Hope Medical Center",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "HIGH",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has Stage IV non-small cell lung cancer (NSCLC).",
        "Patient has a confirmed KRAS G12C mutation.",
        "Patient's ECOG status is 1.",
        "Patient does not have any brain metastases.",
        "Patient's ANC is 3.2, which meets the criterion of ANC \u2265 1,500/mm^3.",
        "Patient's platelets are 245k, which meets the criterion of platelets \u2265 100,000/mm^3."
      ],
      "conflicts": [
        "Patient has had prior therapies including a KRAS inhibitor (pembrolizumab), but the trial requires patients who have failed prior KRAS inhibitors."
      ],
      "uncertainties": [
        "Complete details on liver function tests (LFTs) and creatinine levels are not provided; however, they are stated to be normal and creatinine is 1.1."
      ],
      "confidence": 0.1,
      "reasoning": "The patient has the correct cancer type and KRAS mutation but is excluded due to prior therapies that do not align with trial requirements for previous treatment with KRAS inhibitors.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05074810",
      "title": "A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Sotorasib With or Without Defactinib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "Verastem, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1",
        "Prior therapies: carboplatin/pemetrexed, pembrolizumab (received appropriate treatment with at least one prior systemic regimen)",
        "No brain metastases",
        "Adequate organ function (Creatinine 1.1, LFTs normal, ANC 3.2, platelets 245k)"
      ],
      "conflicts": [
        "Patient has received prior therapies and the trial includes patients who have not been previously treated with a KRAS inhibitor to be included in Part B."
      ],
      "uncertainties": [],
      "confidence": 0.65,
      "reasoning": "The patient's cancer type of NSCLC with KRAS G12C mutation matches the trial's subject. However, due to prior treatments with a G12C inhibitor (pembrolizumab), there is uncertainty regarding the treatment line eligibility as the trial specifies exposure to G12C inhibitors for inclusion criteria. Thus, the patient likely qualifies but requires further verification regarding the treatment line.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05609578",
      "title": "A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a diagnosis of advanced NSCLC with KRAS G12C mutation.",
        "Patient has PD-L1 TPS of 40%.",
        "Patient presents no brain metastases."
      ],
      "conflicts": [
        "Patient has previously received systemic therapy (carboplatin/pemetrexed, pembrolizumab) which may impact eligibility."
      ],
      "uncertainties": [
        "Organ function lab results are clear, but history of treatments used and their timelines for the specific cohort may need more clarity."
      ],
      "confidence": 0.65,
      "reasoning": "The disease type is a match, but the patient has received prior systemic therapies, making it unclear if they are eligible for the trial which seems focused on treatment-naive or first-line patients. Additionally, the PD-L1 TPS is below 50%, qualifying for a specific cohort, but prior treatment history complicates eligibility further.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06545331",
      "title": "A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors",
      "sponsor": "Exelixis",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "MEDIUM",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "ECOG status: 1",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C"
      ],
      "conflicts": [
        "Prior therapies: The patient has received prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) which may not align with trial objectives aimed at treatment-naive patients."
      ],
      "uncertainties": [
        "Specific criteria for biomarker qualification regarding acceptable levels of PD-L1 expression are not provided."
      ],
      "confidence": 0.65,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial conditions, and the ECOG status and age are acceptable. However, the patient has received prior systemic therapies, potentially conflicting with the treatment line criteria if the trial is aimed at treatment-naive patients. This uncertainty affects the overall confidence level.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06130254",
      "title": "Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "LOW",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC with KRAS G12C mutation.",
        "Patient has progressive disease after prior therapies.",
        "ECOG status 1."
      ],
      "conflicts": [
        "Trial requires KEAP1 co-mutation for NSCLC eligibility, which the patient does not have."
      ],
      "uncertainties": [
        "Laboratory values within the screening period: unspecified hemoglobin levels."
      ],
      "confidence": 0.2,
      "reasoning": "The patient's cancer type of NSCLC aligns with the trial. However, the trial requires both KRAS G12C and KEAP1 co-mutations for NSCLC eligibility, which the patient does not possess, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06875310",
      "title": "A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",
      "sponsor": "Mirati Therapeutics Inc.",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Confirmed diagnosis of Stage IV non-small cell lung cancer (adenocarcinoma)",
        "KRAS G12C mutation confirmed by NGS",
        "Measurable disease with new hepatic metastases"
      ],
      "conflicts": [
        "Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) which conflicts with trial's requirement for treatment-naive patients"
      ],
      "uncertainties": [],
      "confidence": 0.15,
      "reasoning": "The patient has a confirmed diagnosis of non-squamous NSCLC with the required KRAS G12C mutation. However, the trial requires treatment-naive patients, and the patient has received prior systemic therapy, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04585477",
      "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)",
      "sponsor": "Stanford University",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has Stage IV NSCLC, while trial includes only Stage I to III NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has Stage IV non-small cell lung cancer, while the trial specifically studies early stage NSCLC (Stage I to III), leading to a clear exclusion based on disease stage.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05261399",
      "title": "A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON).",
      "sponsor": "AstraZeneca",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status: 1"
      ],
      "conflicts": [
        "Patient has NSCLC with KRAS G12C mutation; trial requires EGFR mutation (exon19 deletion, L858R mutation, and/or T790M)."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has non-small cell lung cancer (NSCLC), but his cancer is driven by a KRAS G12C mutation, while the trial targets patients with EGFR mutations. Therefore, the patient is excluded based on the mismatch in required biomarkers.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05578326",
      "title": "Study of Trilaciclib and Lurbinectedin in Small Cell Lung Cancer",
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has non-small cell lung cancer (NSCLC), but trial is for small cell lung cancer (SCLC)."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has NSCLC, while the trial is targeted towards SCLC, clearly excluding eligibility based on disease type.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05500092",
      "title": "An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer",
      "sponsor": "Montefiore Medical Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has previously treated NSCLC (carboplatin/pemetrexed and pembrolizumab), while trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has a diagnosis of NSCLC, which matches the trial's requirement. However, the patient has received prior therapies, which conflicts with the trial's criteria for treatment-naive patients, leading to a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06248606",
      "title": "Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases",
      "sponsor": "Ryan Gentzler, MD",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Cancer type is NSCLC",
        "Patient has KRAS G12C mutation",
        "ECOG status is 1"
      ],
      "conflicts": [
        "Patient has no untreated brain metastases, which is a requirement for the trial"
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial; however, he does not meet the critical inclusion criterion of having untreated brain metastases, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06312137",
      "title": "A Phase 3 Randomized Open-Label Study of Adjuvant Pembrolizumab With or Without MK-2870 in Participants With Resectable Stage II to IIIB (N2) NSCLC Not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy Followed by Surgery",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has Stage IV NSCLC which does not align with the trial's requirement for resectable Stage II to IIIB NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type does not match the trial's indication as they have Stage IV NSCLC, while the trial focuses on resectable Stage II to IIIB NSCLC.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06561386",
      "title": "A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression \u2265 1%",
      "sponsor": "Bristol-Myers Squibb",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has prior systemic anti-cancer therapy (carboplatin/pemetrexed and pembrolizumab), but trial requires treatment-naive participants."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has previously received systemic therapy for their cancer, which conflicts with the trial's requirement for treatment-naive participants.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06593522",
      "title": "A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)",
      "sponsor": "Amgen",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has KRAS G12C mutation, which is excluded by the trial criteria that state tumors harboring KRAS G12C are not eligible."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type is NSCLC, which is being studied in the trial, but the patient's KRAS G12C mutation is specifically excluded from the trial eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06582771",
      "title": "A Phase 2 Study of First-line Sotorasib for Patients With Advanced KRAS G12C-mutant Non-small Cell Lung Cancer",
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has KRAS G12C mutation confirmed by NGS.",
        "Age is 65, which is above the minimum age of 18.",
        "ECOG status is 1, which is acceptable."
      ],
      "conflicts": [
        "Patient has received prior therapies in the advanced setting (carboplatin/pemetrexed and pembrolizumab), while the trial requires no prior therapy in the advanced setting."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has a diagnosis of NSCLC with a KRAS G12C mutation, which matches the trial's condition. However, the patient is not eligible because they have received prior therapies in the advanced setting, while the trial specifically requires treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06793215",
      "title": "A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic treatment (carboplatin/pemetrexed + pembrolizumab), whereas the trial requires treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial's indication, but the trial specifically seeks treatment-naive patients, and the patient has already undergone prior systemic therapy. Thus, the patient is excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06890598",
      "title": "A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy and Safety of Olomorasib in Combination With Standard of Care Immunotherapy in Participants With Resected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer - SUNRAY-02",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has NSCLC.",
        "Patient has KRAS G12C mutation.",
        "Patient has PD-L1 TPS 40%.",
        "ECOG status is 1."
      ],
      "conflicts": [
        "Patient has progressive disease after prior therapies, which does not meet the inclusion criteria for Part B which specifies 'without progression on concurrent platinum-based chemoradiotherapy'."
      ],
      "uncertainties": [
        "No known details about organ function labs specified in the trial eligibility."
      ],
      "confidence": 0.1,
      "reasoning": "The patient does have NSCLC with a confirmed KRAS G12C mutation, but they have progressed after previous treatments, which excludes them from the trial as per exclusion criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT02596490",
      "title": "Couple-Based Meditation for Metastatic Lung Cancer Patients and Their Partners",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Diagnosed with stage IV Non-Small Cell Lung Cancer (NSCLC)",
        "ECOG performance status of 1",
        "No brain metastases"
      ],
      "conflicts": [
        "Currently receiving treatment at MD Anderson Cancer Center is not confirmed in the patient profile.",
        "Patient must have a romantic partner with whom they have resided for a minimum of 6 months, which is not confirmed."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "While the patient's cancer type matches the trial's focus on stage IV NSCLC, the requirement for treatment at MD Anderson Cancer Center and the partner residency condition are not met, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03774758",
      "title": "Circulating Tumor DNA for Risk Stratification in Lung Cancer Screening",
      "sponsor": "University of California, San Francisco",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has non-small cell lung cancer (NSCLC) but the trial focuses on patients undergoing lung cancer screening, which is not a treatment study.",
        "Patient has previously been treated with pembrolizumab which conflicts with inclusion for treatment-naive patients; trial does not specify if it is for previously treated patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches NSCLC; however, the trial is aimed at a screening population rather than a treatment population and it is not clear if previously treated patients are eligible. Therefore, the patient is likely excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05332925",
      "title": "Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC (TUMORIN)",
      "sponsor": "Jun Zhang, MD, PhD",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient is not treatment-naive (previous treatment with pembrolizumab)."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient has previously received pembrolizumab, and the trial is designed for treatment-naive patients. Therefore, the patient is excluded based on the treatment line criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05254184",
      "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer",
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has KRAS G12C mutation as confirmed by NGS.",
        "ECOG status is 1.",
        "Age is 65."
      ],
      "conflicts": [
        "Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) for Stage IV NSCLC which does not meet the trial's requirement for treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) does match the trial, and he has the required KRAS mutation. However, the trial specifically excludes patients who have received prior systemic therapy for this stage of disease, and the patient has had prior treatments, leading to a clear exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06225804",
      "title": "A Phase 1, Open-Label Study of ABSK112 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Non-Small Cell Lung Cancer",
      "sponsor": "Abbisko Therapeutics Co, Ltd",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status is 1",
        "Age is 65",
        "Cancer type is NSCLC",
        "Prior therapies include carboplatin/pemetrexed and pembrolizumab"
      ],
      "conflicts": [
        "Patient is not treatment-naive; has received prior systemic therapies, but the trial requires treatment-naive or previously treated patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type matches the trial indication; however, the patient is not treatment-naive. The trial's criteria for treatment status conflict with the patient's prior therapies, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06712745",
      "title": "Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung",
      "sponsor": "University of Texas Southwestern Medical Center",
      "phase": "Early Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) which conflicts with potential eligibility for treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) aligns with the trial's focus, but the patient's prior systemic therapy renders him ineligible for treatment-naive patient criteria, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06671613",
      "title": "Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer",
      "sponsor": "VA Office of Research and Development",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has prior therapy with pembrolizumab, while the trial requires patients to be treatment-naive or only on PD (L)1 inhibitor alone with 50% PD-L1 expression."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The disease type matches the trial's focus on Stage IV NSCLC. However, the patient has previously been treated with pembrolizumab, making them ineligible as the trial requires treatment-naive patients. As such, the patient is clearly excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04956640",
      "title": "A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a confirmed KRAS G12C mutation.",
        "ECOG status of 1."
      ],
      "conflicts": [
        "Patient has prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) while the trial specifies treatment-naive/first-line patients."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) matches the trial, and he carries the required KRAS G12C mutation. However, he has received prior systemic therapy, which excludes him from this trial that targets treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06253871",
      "title": "A Phase 1/1b Study of IAM1363 in Patients With Advanced Cancers Harboring HER2 Alterations",
      "sponsor": "Iambic Therapeutics, Inc",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC (non-small cell lung cancer) but the trial is specifically for HER2-altered malignancies. No indication of the patient having a HER2 alteration."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type (NSCLC) does not match the trial's focus on HER2 alterations, leading to exclusion based on disease indication.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06447662",
      "title": "A Phase 1 Open-Label Study of PF-07934040 as a Single Agent and in Combination With Other Targeted Agents in Participants With Advanced Solid Tumors Harboring Mutations in the KRAS Gene",
      "sponsor": "Pfizer",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1"
      ],
      "conflicts": [
        "Patient has a KRAS G12C mutation which is excluded for NSCLC as previously treated.",
        "Patient has progressive disease after prior therapies which likely conflicts with required progression after standard treatments."
      ],
      "uncertainties": [],
      "confidence": 0.1,
      "reasoning": "The patient's cancer type, NSCLC with KRAS G12C mutation, is excluded as prior treatment with G12C was undertaken. Given that the trial specifically excludes previously treated G12C mutations in NSCLC, the patient does not meet critical eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05669846",
      "title": "Phase II Feasibility Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC",
      "sponsor": "Diwakar Davar",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has stage IV NSCLC with PD-L1 TPS 40%, but trial requires PD-L1 positive NSCLC defined as 1% or greater, which does not meet the required threshold.",
        "Patient has received prior treatment with pembrolizumab, while trial requires participants who have progressed on treatment with an anti-PD(L)1 ICI."
      ],
      "uncertainties": [],
      "confidence": 0.09,
      "reasoning": "The patient's cancer type matches as stage IV NSCLC, but they do not meet the trial's biomarker requirement of PD-L1 status nor the treatment progression criteria after anti-PD-1 therapy.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03586453",
      "title": "A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor na\u00efve Advanced EGFR Mutant Lung Cancer",
      "sponsor": "Dana-Farber Cancer Institute",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC with KRAS G12C mutation, but trial requires EGFR mutation (L858R or exon 19 deletion) which the patient does not have.",
        "Patient has received prior therapy (carboplatin/pemetrexed and pembrolizumab), while trial appears to target treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient has non-small cell lung cancer (NSCLC) but has a KRAS G12C mutation, while the trial is specifically focused on patients with EGFR mutations. Additionally, the patient has prior systemic therapy which disqualifies him from being treatment-naive as required by the trial.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04486833",
      "title": "A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer",
      "sponsor": "Genprex, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC with KRAS G12C mutation, but the trial is for EGFR-mutant NSCLC.",
        "Patient has prior therapies (carboplatin/pemetrexed, pembrolizumab) and the trial specifies it is for patients who have progressed on osimertinib, which the patient has not received."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's cancer type does not match the trial's focus on EGFR-mutant NSCLC, as the patient has a KRAS mutation. Additionally, the patient has not been treated with osimertinib, which is required for eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05715229",
      "title": "A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC",
      "sponsor": "Hackensack Meridian Health",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status 1",
        "PD-L1 TPS 40%",
        "Age 65",
        "No brain metastases",
        "Creatinine 1.1",
        "LFTs normal",
        "ANC 3.2",
        "platelets 245k"
      ],
      "conflicts": [
        "Patient has prior systemic therapy (carboplatin/pemetrexed + pembrolizumab) while the trial requires patients to be untreated.",
        "Trial requires newly diagnosed, previously untreated Stage IV NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's NSCLC matches the trial's condition; however, the patient has received prior treatment, which is against the trial's eligibility requirements for treatment-naive patients. Therefore, the patient is excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03260491",
      "title": "A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer",
      "sponsor": "Daiichi Sankyo",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status of 1",
        "Cancer type of NSCLC",
        "Mutated KRAS G12C",
        "No brain metastases"
      ],
      "conflicts": [
        "Trial requires EGFR activating mutation, while patient has KRAS G12C mutation which does not meet the trial's criteria for Dose Escalation or Dose Expansion"
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's cancer type is NSCLC, but the trial specifically targets patients with NSCLC harboring specific EGFR activating mutations, which the patient does not have. This leads to a clear exclusion based on the trial's eligibility criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06124118",
      "title": "A Feasibility Study to Evaluate the Addition of Tumor Treating Fields to Treatment of Locally Advanced Stage III NSCLC",
      "sponsor": "University of Utah",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a histologically confirmed diagnosis of NSCLC.",
        "ECOG Performance Status is 1.",
        "Patient is 65 years old, which is within the acceptable age range."
      ],
      "conflicts": [
        "Trial is looking for patients with locally advanced unresectable stage III NSCLC, while patient has Stage IV NSCLC which is not within the inclusion criteria."
      ],
      "uncertainties": [
        "No information provided regarding the ability to operate the NovoTTF-200T System."
      ],
      "confidence": 0.05,
      "reasoning": "The patient's disease does not match the trial's eligibility criteria as it requires stage III NSCLC, whereas the patient has Stage IV NSCLC.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06997497",
      "title": "A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084, Cetuximab, and mFOLFOX6 Versus mFOLFOX6 With or Without Bevacizumab as First-line Treatment of Participants With KRAS G12C-mutant, Locally Advanced Unresectable or Metastatic Colorectal Cancer (KANDLELIT-012)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "KRAS G12C mutation confirmed by NGS"
      ],
      "conflicts": [
        "Patient has previously received systemic anticancer therapy (carboplatin/pemetrexed and pembrolizumab), while trial is for treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's cancer is NSCLC, while the trial is for colorectal cancers. This mismatch clearly indicates exclusion. Additionally, the patient has received prior systemic therapy, which further confirms exclusion based on treatment line criteria.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT03948100",
      "title": "Dyadic Behavioral Interventions to Manage Physical Performance, Symptoms and Quality of Life for Patient Undergoing Radiotherapy and Their Family Caregivers",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has prior therapies (carboplatin/pemetrexed, pembrolizumab) which indicates they are not treatment-naive.",
        "Patient does not have metastatic disease involving the central nervous system, which is a criterion but is irrelevant due to prior treatments."
      ],
      "uncertainties": [],
      "confidence": 0.05,
      "reasoning": "The patient's diagnosis of Stage IV non-small cell lung cancer matches the trial's target indication. However, they have previously received systemic therapy, which excludes them from consideration for a trial that does not accept previously treated patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04093167",
      "title": "A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer",
      "sponsor": "Canadian Cancer Trials Group",
      "phase": "Phase 2/Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has Stage IV non-small cell lung cancer (adenocarcinoma) which matches the trial's study of NSCLC."
      ],
      "conflicts": [
        "PD-L1 TPS score is 40%, but trial requires PD-L1 TPS \u2265 50%."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches the trial indication; however, the patient's PD-L1 TPS score does not meet the required threshold, which leads to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04155034",
      "title": "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has non-small cell lung cancer (NSCLC) while the trial is for small cell lung cancer (SCLC)"
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is non-small cell lung cancer (NSCLC), which does not match the clinical trial that focuses on small cell lung cancer (SCLC). Thus, the patient is clearly excluded based on the disease mismatch.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04253964",
      "title": "Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy",
      "sponsor": "Wake Forest University Health Sciences",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic treatment (carboplatin/pemetrexed, pembrolizumab), which conflicts with the trial requirement of no prior systemic treatment for non-curative intent."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches the trial's focus on non-small cell lung cancer; however, the trial excludes patients who have had prior systemic treatment, which the patient has received.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04317534",
      "title": "A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153",
      "sponsor": "Greg Durm, MD",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "The patient has Stage IV NSCLC, while the trial is for Stage I NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The trial is specifically for Stage I non-small cell lung cancer, while the patient has Stage IV NSCLC, thus making them ineligible.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04302025",
      "title": "NAUTIKA1: A Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Multiple Therapies in Biomarker-selected Patients With Resectable Stages IB-III Non-small Cell Lung Cancer",
      "sponsor": "Genentech, Inc.",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Male participant",
        "ECOG status 1",
        "PD-L1 TPS 40%",
        "KRAS G12C mutation",
        "No brain metastases"
      ],
      "conflicts": [
        "Patient is in Stage IV NSCLC, while trial includes only Stage IB-III NSCLC",
        "Patient has prior treatment including chemotherapy and immunotherapy, while trial requires untreated patients"
      ],
      "uncertainties": [
        "None"
      ],
      "confidence": 0.0,
      "reasoning": "The patient has Stage IV non-small cell lung cancer, which is outside the eligibility criteria of the trial that only accepts resectable stages IB-III. Additionally, the patient has undergone prior systemic therapy, which excludes him from the trial designed for treatment-naive patients.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05118854",
      "title": "A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has a KRAS G12C mutation confirmed by NGS.",
        "ECOG status 1.",
        "Age is above 18.",
        "No brain metastases."
      ],
      "conflicts": [
        "Patient has Stage IV NSCLC, while trial is for patients with stage IIA to IIIB non-squamous NSCLC."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has Stage IV non-small cell lung cancer, which is not eligible for this trial that only includes patients with surgically resectable stage IIA-IIIB disease.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05168566",
      "title": "A Multicenter, Open-label, Phase IIb Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)",
      "sponsor": "Teligene US",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status 1",
        "Age 65",
        "Confirmed KRAS G12C mutation"
      ],
      "conflicts": [
        "Patient has received more than 1 prior line of chemotherapy (carboplatin/pemetrexed + pembrolizumab), while trial requires \u2264 1 prior line."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is NSCLC, which matches the trial's indication. However, the patient has received two prior therapies, which conflicts with the trial's requirement for \u2264 1 prior line of chemotherapy. Therefore, the patient is excluded.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05642572",
      "title": "A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)",
      "sponsor": "SWOG Cancer Research Network",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC with KRAS G12C mutation, but trial requires patients with EGFR mutations.",
        "Patient has previously been treated with osimertinib, whereas this trial requires a sensitizing EGFR mutation and progression on osimertinib."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The trial specifically targets patients with EGFR-mutant NSCLC, while the patient has a KRAS G12C mutation. Additionally, the trial requires documentation of progression on osimertinib, but the patient has already completed treatment with this drug. Therefore, the patient is excluded due to mismatch in cancer type and treatment requirements.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05920356",
      "title": "A Phase 3, Multicenter, Randomized, Open-label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS p.G12C (CodeBreaK 202)",
      "sponsor": "Amgen",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic therapy (carboplatin/pemetrexed and pembrolizumab) which does not meet the trial requirement of no prior therapy in metastatic settings."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is NSCLC, which matches the trial focus, but the participation requirement for treatment-naive patients conflicts with the patient's previous systemic therapies, resulting in exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05789082",
      "title": "A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age 65",
        "ECOG status 1",
        "Cancer type: NSCLC with KRAS G12C mutation",
        "No brain metastases"
      ],
      "conflicts": [
        "Prior treatment with systemic therapy (carboplatin/pemetrexed + pembrolizumab) conflicts with the trial requirement for no prior systemic treatment for advanced unresectable or metastatic NSCLC",
        "Patient has already received treatment for metastatic NSCLC, whereas the trial stipulates it is for treatment-naive patients"
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has received prior systemic therapy for metastatic NSCLC, which directly conflicts with the trial's criteria of being treatment-naive. This leads to a clear exclusion from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT05845671",
      "title": "A Phase 1 / 2, Open Label, Study of Amivantamab (JNJ-61186372) Among Participants With Advanced NSCLC Harboring ALK, ROS1, and RET Gene Fusions in Combination With Tyrosine Kinase Inhibitors",
      "sponsor": "University of Colorado, Denver",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient is \u2265 18 years of age (65 years old)",
        "ECOG status of 1",
        "Patient has advanced and metastatic NSCLC",
        "Adequate organ function as indicated by labs"
      ],
      "conflicts": [
        "Patient has NSCLC with KRAS G12C mutation; trial requires ALK, ROS1, or RET gene fusions.",
        "Patient has prior systemic therapy (carboplatin/pemetrexed, pembrolizumab), whereas trial requires progression on TKI therapies which include ALK or ROS1 fusions."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "Patient's disease type does not match the trial criteria as he has KRAS G12C mutation and is not tested for ALK, ROS1, or RET fusions. Additionally, the patient has received prior systemic therapies not meeting the trial's treatment lines.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06117774",
      "title": "A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy",
      "sponsor": "Amgen",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC (non-small cell lung cancer) while the trial is for SCLC (small cell lung cancer)."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is NSCLC, which does not match the trial's focus on SCLC. Therefore, the patient is excluded based on the disease indication check.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06119581",
      "title": "SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression \u226550% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum Regardless of PD-L1 Expression",
      "sponsor": "Eli Lilly and Company",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has received prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) while the trial is for treatment-naive patients."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches the trial's indication of NSCLC with KRAS G12C mutation. However, the trial requires treatment-naive patients, and the patient has previously received systemic therapy, leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06385262",
      "title": "Safety, Efficacy, and Tumor Immune Microenvironment Changes With Neoadjuvant Chemotherapy and Cemiplimab With or Without Alirocumab in Stage 1B-3A Non-Small Cell Lung Cancer: TOP 2301",
      "sponsor": "Duke University",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status of 1"
      ],
      "conflicts": [
        "Patient has previously received therapy (carboplatin/pemetrexed, pembrolizumab) but the trial requires no prior chemotherapy or treatment for current diagnosis."
      ],
      "uncertainties": [
        "Geographic location eligibility is not explicitly confirmed."
      ],
      "confidence": 0.0,
      "reasoning": "The patient's diagnosis of non-small cell lung cancer (NSCLC) matches the trial's focus, but the trial explicitly excludes patients who have received prior treatment for their current diagnosis. The patient has received prior therapies, resulting in exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06345729",
      "title": "A Phase 3, Randomized, Double-blind, Multicenter Study of MK-1084 in Combination With Pembrolizumab Compared With Pembrolizumab Plus Placebo as Firstline Treatment of Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic NSCLC With PD-L1 TPS \u226550% (KANDLELIT-004)",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC)",
        "Stage IV (M1a, M1b, or M1c) NSCLC"
      ],
      "conflicts": [
        "Patient has prior systemic therapy (carboplatin/pemetrexed, pembrolizumab) while trial requires treatment-naive patients.",
        "PD-L1 TPS is 40% while trial requires PD-L1 TPS \u226550%"
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has previously received systemic therapies, excluding them from this first-line trial requirement, and their PD-L1 TPS does not meet the trial's threshold.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06422143",
      "title": "Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer",
      "sponsor": "Merck Sharp & Dohme LLC",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "ECOG status 1",
        "Age 65",
        "No brain metastases",
        "Normal organ function indicated by creatinine and LFTs"
      ],
      "conflicts": [
        "Patient has non-squamous NSCLC (adenocarcinoma) while the trial is for squamous NSCLC",
        "Patient has received prior systemic therapy with pembrolizumab",
        "Trial is for first-line treatment; patient has previous treatments"
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is adenocarcinoma (non-squamous NSCLC), whereas the trial specifically targets squamous NSCLC. Furthermore, the patient has previously received systemic therapy with pembrolizumab, excluding them from a first-line treatment study.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04712877",
      "title": "LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers",
      "sponsor": "Lung Cancer Mutation Consortium",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has Stage IV NSCLC, but trial requires clinical stage IA2-III lung cancers."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type does not match the eligibility criteria of the trial, as the trial is only for early stage lung cancers (IA2-III), while the patient has Stage IV NSCLC.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04762199",
      "title": "A Phase 1b Safety and Pharmacodynamic Study of MER Tyrosine Kinase Inhibitor, MRX-2843, in Combination With Osimertinib in Advanced EGFR Mutant Non-Small Cell Lung Cancer",
      "sponsor": "Emory University",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Patient has confirmed diagnosis of non-small cell lung cancer (NSCLC)",
        "Patient has ECOG status of 1",
        "Patient has no brain metastases",
        "Patient's age is 65"
      ],
      "conflicts": [
        "Patient has a KRAS G12C mutation; trial is for patients with activating EGFR mutations only",
        "Patient has previous systemic therapy with osimertinib; trial requires treatment-naive patients or those with disease progression on previous EGFR TKIs"
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has a KRAS G12C mutation, while the trial specifically targets activating EGFR mutations. Additionally, the patient has previously been treated with osimertinib, which conflicts with the trial's requirement for treatment-naive participants or those with specific treatment responses.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06252129",
      "title": "Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens",
      "sponsor": "Brigham and Women's Hospital",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC (Stage IV) but the trial specifies subjects with lung nodules eligible for lobectomy without any metastasis.",
        "Patient has metastasis (hepatic) which excludes them from the trial."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's NSCLC is at Stage IV with hepatic metastases, which conflicts with the trial's requirement for subjects without any metastasis. Thus, the patient is excluded from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06566443",
      "title": "Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer",
      "sponsor": "The Methodist Hospital Research Institute",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has Stage IV NSCLC, which is not eligible for this trial that studies early-stage NSCLC (Stage I)."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's NSCLC is Stage IV, whereas the trial is specifically for early-stage NSCLC (Stage I). This leads to a clear exclusion based on the disease type.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT04130516",
      "title": "A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab",
      "sponsor": "Linnaeus Therapeutics, Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04300556",
      "title": "A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FR\u03b1)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor Types",
      "sponsor": "Eisai Inc.",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04589845",
      "title": "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05419375",
      "title": "Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05638295",
      "title": "A Randomized Phase II Study of AMG 510 (Sotorasib) With or Without Panitumumab in Advanced Solid Tumors: A ComboMATCH Treatment Trial",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05892068",
      "title": "Window of Opportunity Analysis of Pre-Operative Tucatinib for Surgically Resected HER2+ Brain Metastases: Understanding Mechanisms of Resistance",
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Trial requires female patients"
    },
    {
      "nct_id": "NCT06401330",
      "title": "Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)",
      "sponsor": "Children's Oncology Group",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Patient age 65 is above maximum age 30"
    },
    {
      "nct_id": "NCT06252649",
      "title": "Phase 3 Multicenter, Randomized, Open-label, Active-controlled Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb for Treatment-na\u00efve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)",
      "sponsor": "Amgen",
      "phase": "Phase 3",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC (non-small cell lung cancer) while the trial is for metastatic colorectal cancer."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is non-small cell lung cancer (NSCLC), while the clinical trial is focused on metastatic colorectal cancer. This clear mismatch results in the patient being excluded from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06412198",
      "title": "A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": "Phase 1/Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Confirmed KRAS G12C mutation status."
      ],
      "conflicts": [
        "Patient has NSCLC, but trial is for metastatic colorectal cancer."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type is non-small cell lung cancer (NSCLC), while the trial is assessing metastatic colorectal cancer (CRC). This critical mismatch in disease/indication disqualifies the patient from eligibility.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06695845",
      "title": "A Phase 2, Open-label, Multicenter Study to Evaluate Efficacy and Safety of Zanidatamab for the Treatment of Participants With Previously Treated HER2-expressing Solid Tumors (DiscovHER PAN-206)",
      "sponsor": "Jazz Pharmaceuticals",
      "phase": "Phase 2",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has non-small cell lung cancer (NSCLC) which is being studied, but must have HER2 overexpression (IHC 3+) which is not indicated in patient data.",
        "The specific requirement for HER2 overexpression (IHC 3+) is not met by the patient."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's cancer type matches the trial indication (NSCLC), but the trial requires HER2 overexpression (IHC 3+), which the patient's profile does not confirm, thus leading to exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT00033137",
      "title": "Birt-Hogg-Dub(SqrRoot)(Copyright) Syndrome: Characterization of the FLCN Disease Gene and Predisposition to Renal Cancer, Cutaneous Fibrofolliculoma and Pulmonary Cysts",
      "sponsor": "National Cancer Institute (NCI)",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT04551378",
      "title": "Impacts of Coronavirus Disease 2019 (COVID-19) Pandemic on Adolescent and Young Adult (AYA) Cancer Patients and Survivors",
      "sponsor": "M.D. Anderson Cancer Center",
      "phase": null,
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Patient age 65 is above maximum age 39"
    },
    {
      "nct_id": "NCT04929223",
      "title": "A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",
      "sponsor": "Hoffmann-La Roche",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05720117",
      "title": "A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants With Advanced Solid Tumors",
      "sponsor": "Pyxis Oncology, Inc",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05876923",
      "title": "The Effects of Acute and Chronic Exercise on the Immune Phenotype of Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients",
      "sponsor": "Mayo Clinic",
      "phase": "Not Applicable",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06555744",
      "title": "A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants With Advanced Solid Tumors",
      "sponsor": "Zymeworks BC Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06804824",
      "title": "A Phase 1/1b, Open-Label, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-159642, a RAS-PI3K\u03b1 Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors",
      "sponsor": "Vividion Therapeutics, Inc.",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT06807619",
      "title": "BrainMet ADePPT (Anticancer Drug Penetration Platform Trial)",
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "fast_filter",
      "supporting_factors": [],
      "conflicts": [],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "",
      "excluded_reason": "Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers"
    },
    {
      "nct_id": "NCT05514717",
      "title": "A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2",
      "sponsor": "Mersana Therapeutics",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [],
      "conflicts": [
        "Patient has NSCLC cancer type, but trial is studying HER2-positive tumors. Patient does not have HER2 positivity as defined by IHC or ISH criteria."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient's NSCLC diagnosis does not align with the trial's focus on HER2-positive tumors, resulting in exclusion.",
      "excluded_reason": null
    },
    {
      "nct_id": "NCT06333951",
      "title": "A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)",
      "sponsor": "Amgen",
      "phase": "Phase 1",
      "status": "Recruiting",
      "match_likelihood": "EXCLUDED",
      "filter_stage": "llm_scored",
      "supporting_factors": [
        "Age: 65",
        "Sex: male",
        "Cancer type: NSCLC",
        "Biomarkers: KRAS G12C",
        "ECOG status: 1",
        "PD-L1: TPS 40%",
        "Brain metastases: none",
        "Country: United States"
      ],
      "conflicts": [
        "Patient has KRAS G12C mutation, but trial requires homozygous MTAP-deletion.",
        "Patient has PD-L1 TPS 40%, but trial requires PD-L1 positive without specific threshold."
      ],
      "uncertainties": [],
      "confidence": 0.0,
      "reasoning": "The patient has NSCLC but fails the required biomarker criteria as they lack homozygous MTAP-deletion. Additionally, their PD-L1 expression is not at the required threshold. Therefore, the patient is excluded.",
      "excluded_reason": null
    }
  ]
}